Pharma stocks buck weak market; Dr Reddy's Labs, Cipla, Lupin up 1-4%

Other pharma stocks including Laurus Labs, JB Pharma, Ipca Labs, Aurobindo Pharma, Abbott India, Natco Pharma and Glenmark also surged 1-5 percent.

Shares of pharma stocks emerged as outliers in a weak market, with prominent names like Dr Reddy's Labs, Cipla, and Lupin rising 1-4 percent on December 19. Other stocks, including Laurus Labs, JB Pharma, Ipca Labs, Aurobindo Pharma, Abbott India, Natco Pharma, and Glenmark, also surged 1-5 percent.

Broad-based gains across most pharma names also lifted the Nifty Pharma index over 1 percent higher, making it the sole sectoral gainer in today's trade.

The sentiment for industry major Dr Reddy's improved after brokerage firm Nomura upgraded its rating to 'buy' from the previous 'neutral' call. In the near term, Nomura sees the sustenance of above-average market growth in India and low-competition injectable launches in the US as key upside catalysts for the drugmaker. The positive views from Nomura helped fuel a nearly 4 percent spike in shares of Dr Reddy's, making it the top gainer on the Nifty 50.

Nomura's expectation of Dr Reddy's benefiting from GLP-1 opportunities in emerging markets also resonated with other pharma players, thereby lifting shares of Cipla, Sun Pharma, and others.

Meanwhile, shares of Lupin also buzzed in trade after the drugmaker received approval from the US Food and Drug Administration for its generic HIV drug.

Follow our market blog for live updates

On the other hand, hopes of improved opportunities for contract drug manufacturing companies like Laurus Labs and Gland Pharma, on the back of Trump's plans to impose heavy tariffs on China, also lifted sentiment.

Similarly, the Indian pharma market is expected to post strong growth in the coming months, especially amidst the ongoing winter season. Consequently, shares of prominent domestic players like JB Chemicals and Ipca Labs surged around 4 percent each.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.